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Introduction: Fluorine-18 fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography
(PET/CT) is a powerful tool for monitoring the response of diffuse large B-cell lymphoma (DLBCL) to therapy, but
the criteria to interpret PET/CT results remain under debate. We investigated the value of post-treatment PET/CT in
predicting the prognosis of DLBCL patients when interpreted according to qualitative visual trichotomous assessment
(QVTA) criteria compared with the Deauville criteria.
Methods: In this retrospective study, final PET/CT scans of DLBCL patients treated with rituximab-based regimens
between October 2005 and November 2010 were interpreted using the Deauville and QVTA criteria. Survival curves were
estimated using Kaplan-Meier analysis and compared using the log-rank test.
Results: A total of 253 patients were enrolled. The interpretation according to the Deauville criteria revealed that 181
patients had negative PET/CT scan results and 72 had positive results. The 3 year overall survival (OS) rate was significantly
higher in patients with negative scan results than in those with positive results (91.6 % vs. 57.5 %, P < 0.001). The
72 patients with positive scan results according to the Deauville criteria were divided into two groups by the
interpretation according to the QVTA criteria: 29 had indeterminate results, and 43 had positive results. The 3 year OS rate
was significantly higher in patients with indeterminate scan results than in those with positive results (91.2 % vs.
33.5 %, P < 0.001) but was similar between patients with negative and indeterminate scan results (91.6 % vs.
91.2 %, P = 0.921).
Conclusions: Compared with the Deauville criteria, using the QVTA criteria for interpreting post-treatment PET/CT scans
of DLBCL patients is likely to reduce the number of false positive results. The QVTA criteria are feasible for
therapeutic outcome evaluation and can be used to guide risk-adapted therapy.
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Diffuse large B-cell lymphoma (DLBCL) is the most
common subtype of non-Hodgkin’s lymphoma, consti-
tuting 30 % to 40 % of all adult non-Hodgkin’s lymph-
oma cases in China. Despite attempts to increase the
efficacy of conventional chemotherapy, treatment with
rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisone (R-CHOP) is not effective in approxi-
mately 40 % of DLBCL patients. The 5 year overall sur-
vival (OS) rates for patients with DLBCL vary from
45 % to 82 %, reflecting the heterogeneous nature of
this disease [1, 2].
The response to treatment is an important outcome
predictor for individual patients. Achieving complete re-
mission after first-line chemotherapy is of paramount
importance because it usually leads to longer survival,
whereas an incomplete response is usually associated
with a poorer outcome [3].
Fluorine-18 fluorodeoxyglucose (18 F-FDG) positron
emission tomography/computed tomography (PET/CT)
is a powerful tool both for primary staging and for
monitoring the response to therapy in DLBCL and is
used in the standardized response assessment criteria
for lymphoma [4–6]. Qualitative visual dichotomous
assessment is the most widely used method to assess
the responses shown on PET/CT scans in the routine
nuclear medicine setting and is the recommended
method for post-treatment response evaluation in the
revised criteria [5]. However, 18 F-FDG is not a highly
specific marker; 18 F-FDG uptake after a few cycles of
chemotherapy may stem from the presence of both persist-
ent viable tumor and local inflammation [7], whereas a sig-
nificant proportion of patients have prolonged survival in
remission conditions despite positive PET/CT scans [8–10].
Here, we report the results of a retrospective study of
patients newly diagnosed with DLBCL and treated with
standard rituximab-based regimens, all of whom under-
went 18 F-FDG PET/CT at the end of first-line chemo-
therapy. In an effort to standardize the interpretation of
PET/CT scans, we evaluated the prognosis predictive
value of final PET/CT (F-PET/CT) scans interpreted ac-
cording to the qualitative visual trichotomous assess-




This retrospective single-arm study enrolled adult pa-
tients with histologically proven, untreated DLBCL. The
study was approved by the Sun Yat-sen University Can-
cer Center ethics committee. We retrieved and reviewed
the clinical and follow-up records of patients who
underwent F-PET/CT between 2005 and 2010. The data
included age, sex, lactate dehydrogenase (LDH) level,international prognostic index (IPI) [11], extranodal in-
volvement, bone marrow biopsy, full laboratory workup,
echocardiography, the presence of relapse and death. Pa-
tients were staged according to the Ann Arbor staging
system [7].
All patients were systematically followed every 3-6 months
for the first 3 years after diagnosis and annually there-
after. At each follow-up time point, patients were either
met at the clinic or contacted by phone to determine
survival. Follow-up data were recorded at scheduled
visits.
18 F-FDG PET/CT imaging
The patients were examined using a dedicated PET/CT
system (Discovery ST-16, GE Health Care, Piscataway,
NJ, USA). They were instructed to fast for 6 h and to ab-
stain from caffeine and cigarettes for 24 h before the
examination. 18 F-FDG (4.4-7.4 MBq/kg) was injected
intravenously, and the patients were then requested to
lie comfortably in a dark room for 60-90 min before the
PET/CT scanning. The patients were scanned from the
calves to the middle part of the femur while lying in a
supine position. CT was performed before PET, and the
resulting data were used to generate an attenuation cor-
rection map for PET. Two-dimensional PET images
were reconstructed with a slice thickness of 3.25 mm
using the ordered subset expectation maximization itera-
tive image reconstruction method. PET, CT, and fused
PET/CT images were generated for review on a Xeleris
computer workstation.
Visual analysis of PET/CT scans
Three nuclear medicine experts interpreted the PET/CT
scans. Clinical information and baseline data were pro-
vided, but no follow-up information was given. Other
causes of false positive scans were ruled out. Based on
the reviewers’ experience, a more detailed set of instruc-
tions was established to resolve potential confounding
variables. The panel agreed that at least two reviewers
would assess the F-PET/CT scans of each patient.
All F-PET/CT images were analyzed using the Deau-
ville 5-point scale: point 1, no residual uptake higher
than the background level; point 2, residual uptake not
higher than the mediastinum uptake level; point 3, re-
sidual uptake higher than the mediastinum uptake level
but lower than the liver uptake level; point 4, residual
uptake moderately increased compared with the liver
uptake level; and point 5, residual uptake markedly in-
creased compared with the uptake level of the liver or
new sites of disease. The Deauville criteria were used for
nodal and extranodal disease: scores of 1-3 were deemed
negative; scores of 4 and 5 were deemed positive.
The QVTA criteria have the same negative criteria as
the Deauville criteria, but different positive criteria. A
Table 1 Characteristics of the 253 patients with diffuse large
B-cell lymphoma (DLBCL)










Low (0 or 1) 137 (54.1)
Low/intermediate (2) 51 (20.2)
High/intermediate (3) 44 (17.4)




IPI, international prognostic index; R, rituximab; CHOP, cyclophosphamide,
doxorubicin, vincristine, prednisone; EPOCH, etoposide, prednisone, vincristine,
cyclophosphamide, doxorubicin
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uptake level and scattered and nonuniform 18 F-FDG
distribution and was deemed indeterminate. A score of 5
was defined as uptake higher than the liver uptake level
and centralized and uniform 18 F-FDG distribution or as
new sites of disease and was deemed positive.
Statistical analysis
Demographic and baseline disease characteristics were re-
corded, censoring the time of observation by November
2013. Because the objective of this analysis was to estimate
the value of F-PET/CT in predicting the prognosis of
DLBCL patients treated with standard rituximab-based
regimens, the primary end point was OS. OS was defined
as the time from the start of treatment to death of any
cause or the last follow-up. The second end point was
progression-free survival (PFS). PFS was defined as the
time from the start of treatment to lymphoma progres-
sion, death of any cause, or the last follow-up. Estimates of
survival were calculated according to the Kaplan-Meier
method and compared with the log-rank test. A two-sided
P value < 0.05 was considered significant. All statistical
analyses were performed using SPSS version 16.0.
Results
Patient characteristics
The clinical characteristics of the 253 patients with his-
tologically confirmed DLBCL are summarized in Table 1.
The median age was 47 years (range, 18-79 years); 67
(26.5 %) patients were ≥ 60 years old. Sixty-five (25.7 %)
patients had IPI scores indicating high-intermediate or
high risk. Nearly half (49.8 %) of the patients had an
Ann Arbor stage I or II tumor.
Treatment and outcome
Twenty-one (8.3 %) patients underwent surgery before
chemotherapy. R-CHOP was the most commonly used
primary chemotherapy regimen (90.1 %). Twenty-five
(9.9 %) patients received rituximab, etoposide, prednis-
one, vincristine, cyclophosphamide, and doxorubicin
(R-EPOCH) as the first-line chemotherapy regimen.
The chemotherapy plan was changed for 9 (3.6 %) pa-
tients because of progression after 4 cycles of R-CHOP.
Forty-five (17.8 %) patients received combined modality
therapy with 4 cycles of R-CHOP or R-EPOCH followed by
involved-field radiotherapy. All F-PET/CT scans were com-
pleted less than 3 months after the completion of primary
treatment.
At a median follow-up of 47 months (range, 3-
101 months), 54 (21.3 %) patients died of progressive
disease (n = 41), infection (n = 5), heart failure (n = 2),
renal failure (n = 1), lung cancer (n = 1), suicide (n = 1),
or unknown causes (n = 3).PET/CT characteristics
According to the Deauville criteria, 181 patients had nega-
tive F-PET/CT scan results and 72 had positive results. Ac-
cording to the QVTA criteria, the 72 positive patients were
divided into two groups: indeterminate (n = 29, Fig. 1) and
positive (n = 43, Fig. 2).
Among the 181 patients with negative results, 17 patients
relapsed, and 19 died of progressive disease (n = 12), infec-
tion (n = 3), heart failure (n = 1), lung cancer (n = 1), or
unknown causes (n = 2) by the end of follow-up.
Among the 29 indeterminate patients, 6 underwent bi-
opsy following F-PET/CT. Of the 6 patients, none were
positive, and 4 remained disease-free by the end of
follow-up. Among the 29 patients, 9 relapsed, but only 3
died of progressive disease by the end of follow-up.
Among the 43 patients with positive results according
to the QVTA criteria, 33 (76.7 %) died by the end of
follow-up. The median survival was 23 months.Prognosis predictive value of F-PET/CT according to the
Deauville criteria
The 3 year OS rate was 91.6 % (95 % confidence inter-
val [CI], 87.5 %-95.7 %) for patients with negative F-PET/
CT scan results and 57.5 % (95 % CI, 46.5 %-68.5 %) for pa-
tients with positive results. The 3 year OS rate was signifi-
cantly higher in patients with negative results than in
patients with positive results (chi-square = 56.32, P < 0.001)
(Fig. 3a).
Fig. 1 Fluorine-18 fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT) scans of diffuse large B-cell
lymphoma (DLBCL) with a score of 4. (a), baseline PET/CT; (b), final PET/CT (F-PET/CT). A 26 year-old woman with bulky mediastinal uptake on baseline
PET/CT, which was interpreted as indeterminate on F-PET/CT using the qualitative visual trichotomous assessment (QVTA) criteria; the residual foci (red
arrow) were diagnosed and scored as 4. However, the Deauville criteria interpreted the scan as positive. The patient was alive and in
complete remission 41 months after treatment initiation
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Fig. 2 PET/CT scans of DLBCL with a score of 5 in a 45 year-old man. (a), baseline PET/CT; (b), F-PET/CT. Baseline PET/CT shows an Ann Arbor
stage IV tumor, which was interpreted as positive on F-PET/CT using the QVTA criteria; the residual foci (red arrow) were diagnosed and scored
as 5. This patient received involved-field radiotherapy after 6 cycles of chemotherapy using rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) regimen, but the disease progressed, and the patient died 31 months after treatment initiation
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Fig. 3 Kaplan-Meier survival curves based on PET/CT findings in 253 patients with DLBCL. (a), overall survival (OS) curves of patients with positive
(n = 72) and negative (n = 181) F-PET/CT scans according to the Deauville criteria. (b), OS curves of patients with positive (n = 43), indeterminate
(n = 29), and negative (n = 181) F-PET/CT scans according to the QVTA criteria. (c), progression-free survival (PFS) curves of patients with negative (n = 181)
and indeterminate (n = 29) F-PET/CT scans according to the QVTA criteria
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QVTA criteria
The 3 year OS rate was significantly higher in patients
with indeterminate results than in patients with positive
results (91.2 % [95 % CI, 87.1 %-95.3 %] vs. 33.5 % [95 %
CI, 19.5 %-47.5 %], chi-square = 147.98, P < 0.001), but
there was no significant difference between patients with
negative and indeterminate results (91.6 % vs. 91.2 %,
chi-square = 0.01, P = 0.921) (Fig. 3b).
The 3 year PFS rate was significantly higher in patients
with negative results than in patients with indeterminate
results (89.3 % [95 % CI, 84.8 %-93.9 %] vs. 73.1 % [95 %
CI, 56.7 %-89.7 %], chi-square = 28.76, P < 0.001)
(Fig. 3c).
Discussion
In this study, we assessed the value of F-PET/CT in pre-
dicting the prognosis of DLBCL and compared the
Deauville criteria and QVTA criteria for interpreting the
F-PET/CT scans in a histologically homogeneous series
of patients with DLBCL. The present study demon-
strated that F-PET/CT can predict long-term prognosis.
As previously reported, patients with negative F-PET/
CT scans live longer than those with positive F-PET/CT
scans [12-14]. In our study, the 3 year OS rate was sig-
nificantly higher in patients with negative F-PET/CT
scan results than in patients with positive results, as
interpreted according to the Deauville criteria (91.6 %
vs. 57.5 %, P < 0.001).
When the QVTA criteria were used, 29 patients with
F-PET/CT scans interpreted as positive according to the
Deauville criteria were classified as indeterminate.
Among them, 9 relapsed, but only 3 died of progressive
disease by the end of follow-up. Twenty patients
achieved complete remission. Six of the 29 patients
underwent biopsy following F-PET/CT, and none werepositive. Based on these findings, the F-PET/CT scan re-
sults for most of the 29 patients, as interpreted accord-
ing to the Deauville criteria, were evidently false
positive. The 3 year OS rate for the patients with inde-
terminate results was 91.2 %; their outcomes were more
similar to those of the patients with negative results
compared with patients with positive results. Although
the 3 year PFS rate was lower in patients with indeter-
minate results than in patients with negative results
(73.1 % vs. 89.3 %), there was no significant difference in
the 3 year OS rate between patients with negative and
indeterminate results (91.6 % vs. 91.2 %).
Patients with positive F-PET/CT scans should undergo
more aggressive treatment, including a complete course of
chemotherapy with a high-dose radiotherapy or a high-
dose therapy such as autologous stem cell rescue. Most of
the 29 patients with positive F-PET/CT scans, as inter-
preted by the Deauville criteria, had false positive results.
This means that the aggressive (i.e., toxic) treatment they
received was unnecessary. Whether withholding aggres-
sive treatment will affect the long-term survival of such
patients remain uncertain; thus, further prospective stud-
ies are warranted.
It is possible that the false positive scans were due to
18 F-FDG being a marker that lacks high specificity and
that is taken up in infectious and inflammatory
processes [15, 16]. It is also possible that the use of im-
munotherapy increased lesion inflammation. Antibody-
mediated cellular cytotoxicity and complement activation
are important mechanisms of action of rituximab [10,
17]; both processes attract mediators of inflammation
to the tumor site. The various uses of rituximab in pre-
vious studies in a minority of patients [13, 18] com-
pared with its use in all patients in our study may
explain the high rate of 18 F-FDG positivity unrelated to
tumor activity. In this study, using the QVTA criteria
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interpretations.
DLBCLs are relatively heterogeneous and, in a few
cases, can switch their genetic or immunohistochemical
phenotype and transform into other lymphomas or carry
more than one malignant clone [19]. Therefore, the ac-
quisition of drug resistance in lymphoma is driven in
part by the inherent genetic heterogeneity of DLBCL
and the instability of the tumor cells. The emergence of
acquired chemoresistance prevents the successful treat-
ment of DLBCL [20]. It is expected that most chemosen-
sitive tumor cells are killed, but chemoresistant tumor
cells continue to proliferate to form clumps. It is ex-
pected that the clumps formed by these chemoresistant
tumor cells have the same metabolic activity and show
clearly uniform high focal 18 F-FDG uptake on PET/CT
scans. Based on this assumption, this study considered
only centralized and uniform residual mass 18 F-FDG
distribution as positive.
The value of PET/CT in prognostic prediction for ag-
gressive lymphomas is distinguishing. Although patients
with positive F-PET/CT scans, as interpreted by the
Deauville criteria, had poorer OS compared with the pa-
tients with negative F-PET/CT scans, the 3 year OS rate
remained 57.5 %. When the QVTA criteria were applied,
only 43 patients were classified as positive. Of these pa-
tients, 33 (76.7 %) died by the end of follow-up. The me-
dian survival was 23 months. The 3 year OS rate of the
patients with positive results decreased to 33.5 %.
Given the retrospective data collection and relative
disparity in treatment types, we acknowledge that this
study had limitations and potential biases.
Nevertheless, this retrospective study emphasizes that
F-PET/CT interpreted using the QVTA criteria is feas-
ible for therapeutic response evaluation and can be used
to guide risk-adapted therapy. Compared with the Deau-
ville criteria, the QVTA criteria can distinguish high-risk
patients with poor outcomes more accurately. This in-
formation may be useful for objectively tailoring risk-
adapted consolidation strategies.
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